UK markets open in 4 hours 32 minutes
  • NIKKEI 225

    28,746.49
    -5.13 (-0.02%)
     
  • HANG SENG

    23,874.48
    -206.04 (-0.86%)
     
  • CRUDE OIL

    71.70
    +3.55 (+5.21%)
     
  • GOLD FUTURES

    1,794.70
    +9.20 (+0.52%)
     
  • DOW

    34,899.34
    -905.06 (-2.53%)
     
  • BTC-GBP

    43,024.07
    +2,015.98 (+4.92%)
     
  • CMC Crypto 200

    1,430.02
    -25.39 (-1.74%)
     
  • ^IXIC

    15,491.66
    -353.54 (-2.23%)
     
  • ^FTAS

    4,020.38
    -146.90 (-3.53%)
     

atai Life Sciences to Participate in Upcoming November Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it will participate in the following upcoming investor conferences in November:

Presentation details can be found below:

  • Berenberg US CEO Conference 2021
    Format: 1x1 Meetings
    Dates: Tuesday, November 9th, 2021 – Wednesday, November 10th, 2021

The presentations and archived webcasts will also be accessible in the Events section of atai’s website.

About atai Life Sciences

atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to acquiring, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.

atai's business model combines funding, technology, scientific and regulatory expertise with a focus on psychedelic therapy and other drugs with differentiated safety profiles and therapeutic potential. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies, seeking to effectively treat and ultimately heal mental health disorders.

atai's mission is to bridge the gap between what the mental healthcare system currently provides and what patients need. atai is headquartered in Berlin, with offices in New York and London. For more information, please visit www.atai.life.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the important factors discussed under the caption “Risk Factors” in atai's prospectus pursuant to Rule 424(b) filed with the U.S. Securities and Exchange Commission (“SEC”) on June 21, 2021, as such factors may be updated from time to time in atai's other filings with the SEC. atai disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law.

Contact Information

Investor Contact:
Chad Messer
VP, Investor Relations, atai Life Sciences
Email: chad@atai.life

Media Contact:
Camilla Dormer
VP, Communications, atai Life Sciences
Email: camilla@atai.life


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting